Logo image of ARCT

ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock News

NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD

12.03  -0.17 (-1.39%)

After market: 12.03 0 (0%)

ARCT Latest News, Press Relases and Analysis

News Image
15 days ago - Chartmill

Which stocks are moving before the opening bell on Tuesday?

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Mentions: SGMO CHRS DDD AXDX ...

News Image
16 days ago - Chartmill

Which stocks are moving after the closing bell on Monday?

The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Mentions: SGMO ARWR MVIS DGLY ...

News Image
13 days ago - Yahoo Finance

Take-Two Interactive Stock Slips After 'GTA 6' Maker's Outlook Comes Up Short

Take-Two Interactive reported fiscal fourth-quarter revenue that topped analysts’ expectations, but the gaming company's net loss and forecast disappointed.

Mentions: COIN TTWO UNH DE ...

News Image
13 days ago - Yahoo Finance

AMAT Earnings: Demand Holding Up So Far

Applied Materials beat analyst expectations for earnings but missed on revenue. The company said that customer demand hasn’t changed due to an uncertain economic environment. Applied Materials’ outlook for the third quarter included wide ranges for revenue and adjusted earnings per share.

Mentions: AMAT WMT ADCT ENTA ...

News Image
13 days ago - Yahoo Finance

Cava: Rapid Growth but Some Concerns

Fast-casual restaurant company Cava reported revenue and earnings that handily beat expectations. Same-restaurant sales growth of 10.8% was especially impressive. The company's forecast calls for same-restaurant sales growth to decelerate as the year goes on.

Mentions: CAVA TSHA TTWO AMAT ...

News Image
13 days ago - Zacks Investment Research

Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade

The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News Image
16 days ago - Zacks Investment Research

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: BOLT

News Image
23 days ago - Zacks Investment Research

Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mentions: TECH

News Image
3 months ago - CSL

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the...

News Image
6 months ago - Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics to Attend Upcoming Investor Conferences

News Image
6 months ago - Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

News Image
7 months ago - Meiji Seika Pharma Co., Ltd. and ARCALIS, Inc.

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.